Eli Lilly (LLY) R&D In Process (2016 - 2025)
Historic R&D In Process for Eli Lilly (LLY) over the last 16 years, with Q4 2025 value amounting to $528.8 million.
- Eli Lilly's R&D In Process rose 15325.67% to $528.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 billion, marking a year-over-year decrease of 1191.43%. This contributed to the annual value of $2.9 billion for FY2025, which is 1181.82% down from last year.
- As of Q4 2025, Eli Lilly's R&D In Process stood at $528.8 million, which was up 15325.67% from $655.7 million recorded in Q3 2025.
- In the past 5 years, Eli Lilly's R&D In Process registered a high of $3.0 billion during Q3 2023, and its lowest value of $25.0 million during Q2 2021.
- Moreover, its 5-year median value for R&D In Process was $224.4 million (2022), whereas its average is $594.7 million.
- Per our database at Business Quant, Eli Lilly's R&D In Process tumbled by 8966.09% in 2021 and then soared by 467564.1% in 2023.
- Quarter analysis of 5 years shows Eli Lilly's R&D In Process stood at $471.8 million in 2021, then tumbled by 49.11% to $240.1 million in 2022, then soared by 158.23% to $620.0 million in 2023, then tumbled by 66.32% to $208.8 million in 2024, then skyrocketed by 153.26% to $528.8 million in 2025.
- Its R&D In Process stands at $528.8 million for Q4 2025, versus $655.7 million for Q3 2025 and $153.8 million for Q2 2025.